[Guidelines for the diagnosis and treatment of pulmonary hypertension]
- PMID: 20206062
- DOI: 10.1016/j.rmr.2009.11.013
[Guidelines for the diagnosis and treatment of pulmonary hypertension]
Abstract
Introduction: A joint Task Force of the ESC and of the ERS has developed guidelines on the diagnosis and treatment of pulmonary hypertension (PH) to provide updated information on the management of patients with this condition.
State of the art: The term pulmonary hypertension (PH) describes a group of devastating and life-limiting diseases, defined by mean pulmonary artery pressure >25 mmHg at rest. The diagnosis of PH requires a series of investigations intended to confirm the diagnosis, clarify the clinical group and the specific aetiology and an algorithm for this is proposed. Several drugs are currently approved to try to correct endothelial dysfunction. They lead to a significant improvement in the prognosis of patients who are in NYHA functional class II, III or IV. The evaluation of the severity of PH has a pivotal role in the choice of initial treatment and evaluation of the response to therapy in individual patients.
Perspective: These guidelines should be widely disseminated and implemented in order to improve the management of patients with PH.
Conclusion: These guidelines summarise recent advances in the understanding and management of PH.
Copyright 2010 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Comment in
-
[Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].Rev Mal Respir. 2010 Feb;27(2):103-5. doi: 10.1016/j.rmr.2009.12.007. Epub 2010 Jan 25. Rev Mal Respir. 2010. PMID: 20206056 French. No abstract available.
-
[New international guidelines on pulmonary hypertension].Rev Mal Respir. 2010 Feb;27(2):110-1. doi: 10.1016/j.rmr.2010.01.014. Rev Mal Respir. 2010. PMID: 20206059 French. No abstract available.
Similar articles
-
[Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].Rev Mal Respir. 2010 Feb;27(2):103-5. doi: 10.1016/j.rmr.2009.12.007. Epub 2010 Jan 25. Rev Mal Respir. 2010. PMID: 20206056 French. No abstract available.
-
Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.Eur Respir J. 2007 Mar;29(3):432-4. doi: 10.1183/09031936.00001607. Eur Respir J. 2007. PMID: 17329488 No abstract available.
-
Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):550-7. doi: 10.1177/1074248414528066. Epub 2014 Apr 17. J Cardiovasc Pharmacol Ther. 2014. PMID: 24742768
-
An evidence-based approach to the management of pulmonary arterial hypertension.Curr Opin Cardiol. 2006 Jul;21(4):385-92. doi: 10.1097/01.hco.0000231410.07426.9b. Curr Opin Cardiol. 2006. PMID: 16755209 Review.
-
Novel therapeutic approaches in pulmonary arterial hypertension: focus on tadalafil.Drugs Today (Barc). 2011 Feb;47(2):145-56. doi: 10.1358/dot.2011.47.2.1544337. Drugs Today (Barc). 2011. PMID: 21431102 Review.
Cited by
-
Delivering telemedicine interventions in chronic respiratory disease.Breathe (Sheff). 2014 Sep;10(3):198-212. doi: 10.1183/20734735.008314. Breathe (Sheff). 2014. PMID: 26843894 Free PMC article. No abstract available.
-
Life-threatening complications of adult-onset Still's disease.Clin Rheumatol. 2014 Mar;33(3):305-14. doi: 10.1007/s10067-014-2487-4. Epub 2014 Jan 17. Clin Rheumatol. 2014. PMID: 24435354 Free PMC article. Review.
-
Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease.Clin Med Insights Oncol. 2015 Sep 1;9:75-9. doi: 10.4137/CMO.S26537. eCollection 2015. Clin Med Insights Oncol. 2015. PMID: 26380562 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials